Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)GlobeNewsWire • 06/10/22
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual CongressGlobeNewsWire • 05/12/22
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial ResultsGlobeNewsWire • 05/10/22
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation SymposiumGlobeNewsWire • 05/06/22
Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor EventGlobeNewsWire • 04/11/22
Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/15/22
Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022GlobeNewsWire • 03/08/22
Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare ConferencePRNewsWire • 11/22/21
Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial ResultsPRNewsWire • 11/10/21
Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021PRNewsWire • 11/02/21
Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain PenetrationPRNewsWire • 10/07/21
Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC ConferencePRNewsWire • 10/01/21
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial ResultsPRNewsWire • 08/16/21
Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021PRNewsWire • 07/27/21
Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021PRNewsWire • 06/29/21
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial ResultsPRNewsWire • 05/12/21
Cogent Biosciences, Inc. (COGT) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/16/21
Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial ResultsPRNewsWire • 03/16/21
Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of DirectorsPRNewsWire • 02/22/21